Skip to main content
LFVN
NASDAQ Life Sciences

LifeVantage Reports Steep Q3 Revenue & Profit Declines, Lowers Guidance Amidst Operational Challenges

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$4.9
Mkt Cap
$76.829M
52W Low
$3.9
52W High
$15
Market data snapshot near publication time

summarizeSummary

LifeVantage reported significantly weaker-than-anticipated Q3 fiscal 2026 financial results, with substantial declines in revenue and profitability, and lowered its full-year guidance, despite increasing its quarterly dividend.


check_boxKey Events

  • Significant Revenue Decline

    Third-quarter revenue decreased 25.2% year-over-year to $43.7 million, with Americas revenue down 28.9% and Asia/Pacific & Europe revenue down 7.7%.

  • Sharp Profitability Drop

    Diluted earnings per share fell 57.7% to $0.11, and Adjusted EBITDA decreased 50% to $3.2 million compared to the prior year period.

  • Lowered Fiscal Year Guidance

    The company anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted EPS to be at the lower end of its previously issued guidance range.

  • Dividend Increase Amidst Weakness

    LifeVantage declared an 11.1% increase in its quarterly cash dividend to $0.05 per common share, despite the poor financial performance.


auto_awesomeAnalysis

LifeVantage continues to face significant operational headwinds, as evidenced by the substantial year-over-year declines across all key financial metrics. The 25.2% drop in revenue, coupled with over 50% reductions in diluted EPS and Adjusted EBITDA, indicates a deteriorating financial position. The inventory obsolescence charge and the decision to guide towards the lower end of previous fiscal year expectations further underscore these challenges. While the company increased its dividend and continued its share repurchase program, these actions are largely overshadowed by the severe operational underperformance. Investors should be highly concerned about the company's ability to stabilize and reverse these negative trends.

At the time of this filing, LFVN was trading at $4.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.8M. The 52-week trading range was $3.90 to $15.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed LFVN - Latest Insights

LFVN
May 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
LFVN
May 06, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
LFVN
May 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
LFVN
Apr 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
LFVN
Apr 16, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
9
LFVN
Apr 02, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
LFVN
Mar 02, 2026, 6:44 PM EST
Filing Type: 4
Importance Score:
7
LFVN
Feb 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
9
LFVN
Feb 04, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9